Summary

• Novo Nordisk is losing GLP-1 and diabetes market share in key regions as Eli Lilly's Zepbound and Mounjaro gain U.S. leadership.
• NVO's latest GLP-1 drug delivered weaker weight loss than Eli Lilly's, clouding the outlook for the company's next wave of obesity drugs.
• Competition and drug pricing regulations are driving negative margin surprises. I expect these headwinds to persist.
• Semaglutide patents are expiring in several large ex-US markets, enabling cheap generics that could cannibalize Ozempic and Wegovy over time and pressure gross margins further.
• Despite trading at a large discount to its historical and sector PEs, Novo Nordisk's weak technicals and deteriorating fundamentals argue against a near-term rebound.

Elevator pitch

I see a lot of challenges with Novo Nordisk (NVO) (NOVO:CA) (NONOF):

1. Novo Nordisk's share in the obesity and diabetes market is eroding
2. Pricing headwinds are leading to margin deterioration
3. Patent expirations are another

8.03K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.